Developer docs
API playgroundTry for free, no card

Search company profiles

Micregen

Full company profile

uuid000ft2s

Namestring
Micregen
Legal namestring
Micregen Ltd
Websiteurl
micregen.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Micregen is a privately held UK biotechnology company developing cell-free, stem cell-derived therapeutics through its proprietary Secretomix® platform. Founded in 2015 by Barry Sharples and Stephen Ray, the company is headquartered at Thames Valley Science Park in Reading with a commercial office at Alderley Park, Cheshire, and operates with a lean team of 11–50 staff. Its lead therapeutic candidate, MRG1061, is being advanced toward combined Phase I/II clinical trials in the UK for two neonatal orphan indications — necrotising enterocolitis (NEC) and bronchopulmonary dysplasia (BPD) — both of which lack effective pharmacological treatments and carry peak forecasted annual sales above $1 billion each.

The Secretomix® platform produces multi-factorial biologics — including miRNA, extracellular vesicles (exosomes), cytokines, anti-inflammatory factors, lipids, and growth factors — from a proprietary GMP-certified allogeneic stem cell bank. Products are cell-free, allogeneic, scalable, storable under standard (non-ultra-cold) conditions, and administerable off-the-shelf, addressing the principal limitations of conventional stem cell therapies (graft rejection, graft-versus-host disease, tumor formation, ultra-cold logistics). The platform has produced more than 2,000 characterized components in lead formulations, with a completed suite of in-process, potency, and release assays supporting clinical-grade manufacture. Beyond the lead neonatal program, Micregen is pursuing preclinical programs in neurodegeneration (Alzheimer's, MND/ALS) and hallmarks-of-ageing applications.

Micregen is pre-revenue and funded to date by approximately £5.4 million in cumulative capital, comprising a £5 million funding round completed in April 2021 and a £395,000 Innovate UK Smart Award granted in September 2018. The company is currently raising an investment round to fund Phase I/II clinical development. It holds an MHRA Innovation Passport, ILAP membership (December 2022), UKRI Scale-Up Programme selection (January 2023), and the UK Pharma Industry Awards Innovation of the Year (2023), and is supported by collaborations with Great Ormond Street Hospital, SickKids Toronto, Washington University, and the University of Bradford. Future revenue, once approved, is expected from sale of orphan-disease therapeutics distributed via hospital pharmacies and specialty channels; pricing for investigational products is not publicly disclosed.

Short descriptiontext

Micregen is a privately held UK biotechnology company developing cell-free, stem cell-derived therapeutics via its proprietary Secretomix® platform, with lead candidate MRG1061 advancing toward clinical trials for neonatal orphan diseases NEC and BPD.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersReading, United Kingdom
HQ citystring
Reading
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
stem cell therapeutics, regenerative medicine, cell-free biologics, secretome therapeutics, neonatal orphan drugs
Industry4 codes
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Regenerative Medicine Biologics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Therapeutic Product Revenue
TypeOne Time License
Description

Pre-revenue biotech company developing stem cell secretome therapeutics. Future revenue expected from sale of approved therapeutic products targeting orphan diseases (NEC, BPD) and broader degenerative/age-associated conditions. The company is currently in investment round to fund clinical trials.

micregen.com
2Investment Capital
TypeLicensing Royalties
Description

Privately held company funded by founders, angel investors, and life science professionals. Completed £5m funding round in 2021 and £395k Innovate UK Smart Award in 2018. Currently raising capital for clinical development.

micregen.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Secretomix®
Description

Proprietary platform technology for producing cell-free, stem cell-derived secretome therapeutics for regenerative medicine applications.

micregen.com
Core offering1 text field

Micregen develops proprietary cell-free, stem cell-derived secretome therapeutics using its Secretomix® platform, produced from a GMP-certified allogeneic stem cell bank. Its lead therapeutic candidate, MRG1061, is being advanced toward clinical trials for neonatal orphan diseases including necrotising enterocolitis (NEC) and bronchopulmonary dysplasia (BPD), with additional preclinical programs targeting neurodegeneration (Alzheimer's, MND/ALS) and age-associated degenerative conditions. The company is pre-revenue and currently raising capital to fund combined Phase I/II clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Measurable preservation of memory function in preclinical Alzheimer's models
+4 more records
Product overview1 text field

Micregen offers a unified platform technology called Secretomix®, which generates cell-free stem cell-derived therapeutic products. The platform produces multi-component biologics including miRNA, extracellular vesicles (exosomes), cytokines, anti-inflammatory factors, lipids, and proteins that act to enhance tissue repair and regeneration. The lead therapeutic candidate MRG1061, derived from this platform, is advancing toward clinical trials for neonatal conditions. The Secretomix® platform is designed to create various secretome formulations targeting conditions from rare pediatric diseases to age-associated degenerative conditions.

Product and service2 records
1Secretomix® Platform
CategoryRegenerative Medicine / Cell-Free Biologic Platform
Description

Proprietary cell-free, stem cell-derived secretome therapeutic platform. Secretomix® products are multi-component biologics (miRNA, extracellular vesicles/exosomes, cytokines, anti-inflammatory factors, lipids, and proteins including growth factors) produced from a GMP-certified allogeneic stem cell bank. The platform yields scalable, storable, off-the-shelf therapeutics that avoid graft rejection, graft-versus-host disease and tumour risk and can be administered immediately at the point of care.

2MRG1061
CategoryLead Therapeutic Candidate (Neonatal Orphan Disease)
Description

Micregen's lead Secretomix® therapeutic candidate, a tailored combination of regenerative and anti-inflammatory factors designed to reduce intestinal injury, promote healing and improve survival outcomes in preterm infants with necrotising enterocolitis (NEC) and bronchopulmonary dysplasia (BPD) — orphan neonatal diseases with no effective pharmacological treatments today and combined peak-sales potential above $2B.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-17
Description

Micregen featured as 'Industry Partner' in Nature's Pediatric Research paper for NEC-ACCELERATOR (NECrotizing Enterocolitis-ACceleration of CELl-based & Regenerative medicine Advancements for Translation in neOnates). The consortium aims to enhance clinical translation of stem cell-based potential treatments for NEC in neonates. This partnership validates Micregen's scientific approach and provides peer-reviewed publication support.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

SickKids is Canada's most research-intensive hospital and No.1 paediatric hospital in the world (2022 Newsweek). Micregen collaborates on various preclinical studies. Dr. Augusto Zani serves as Staff Surgeon and has made landmark discoveries in amniotic fluid stem cells. Preclinical studies conducted in USA, UK, and Canada.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

GOSH ranked No. 3 paediatric hospital in the world (2022 Newsweek). Micregen has worked with GOSH specialists for over ten years on preclinical studies and clinical advice for trial preparation. MRC grant awarded to partnership for PhD programme on Secretomix® as therapeutic option in NEC, led by Dr. Loukogeorgakis and Dr. Sivaraj.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Collaborating on validation of Secretomix® as a therapeutic for neurodegeneration. Studies designed to determine efficacy of Secretomix® in various disease models for Alzheimer's and Motor Neurone Disease.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Collaborating with world-renowned neonatal surgeon and professor on research into Bronchopulmonary Dysplasia and other neonatal lung indications. Washington University is recognized as one of the top 10 medical schools in the United States.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Regulatory advisors specializing in pharma, biotech, and spinouts supporting new medicine development. Boyds has advised Micregen since 2018 with extensive experience in novel advanced biologic therapies and trusted relationships with regulatory bodies, enabling support in scenarios with limited or no precedents.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Corporate lawyers first established in 1775, globally recognized with clients including many UK FTSE100 listed companies. Their cross-disciplinary healthcare team has in-depth knowledge across virtually every area of healthcare.

Strategic tierSecondaryTypeImplementation/ SI/ Consulting Partner
Description

One of the North West's leading independent firms of Chartered Accountants and Business Advisors providing financial and business advisory services.

Strategic tierMinorTypeOthers
Description

Founded in 1871, Handelsbanken is one of the world's strongest banks with home markets in Denmark, Finland, Netherlands, Norway, Sweden, and the UK, providing banking services to Micregen.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Micregen sponsored the 37th International Symposium on Pediatric Surgical Research 2024 held at Karolinska Institute in Stockholm, Sweden. Conference united clinicians and researchers engaged in pioneering research on pediatric diseases.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Micregen Co-founder Barry Sharples was one of 10 exclusive global speakers at the invite-only 2024 Longevity Investors Conference in Gstaad, Switzerland. Event brought together leading figures in longevity including Eric Verdin (Buck Institute), Dr. Nir Barzilai, Aubrey de Grey, and Bryan Johnson.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Athersys
TypeBroad incumbent
Description

Athersys develops MultiStem, an allogeneic stem cell therapy for inflammatory, neurological, and acute conditions. A broader incumbent in regenerative cell therapy with multi-indication ambitions similar to Micregen's pipeline breadth.

2Pluristem Therapeutics
TypeBroad incumbent
Description

Pluristem develops placenta-derived allogeneic cell therapies for inflammatory, ischemic, and hematological conditions. Comparable as a broader stem cell therapy incumbent targeting similar regenerative and anti-inflammatory mechanisms.

TypeDirect peer
Description

Evox is a UK-based biotech engineering exosomes for delivery of nucleic acids and proteins to treat rare diseases. Directly comparable to Micregen in leveraging extracellular vesicles/secretomes as a therapeutic modality and in targeting rare and serious diseases.

4Cynata Therapeutics
TypeDirect peer
Description

Cynata develops iPSC-derived mesenchymal stem cell therapies with an off-the-shelf, scalable manufacturing model. Comparable in offering allogeneic, scalable stem cell-derived therapeutics, including in inflammatory and rare disease indications.

TypeBroad incumbent
Description

Mesoblast is a late-stage commercial regenerative medicine company with allogeneic cell therapies (e.g., remestemcel-L) for inflammatory and rare diseases. A broader incumbent in the cell-therapy regenerative medicine space overlapping Micregen's anti-inflammatory mechanism.

TypeDirect peer
Description

ILIAS Biologics develops engineered exosomes (EXO-LOAD technology) for therapeutic delivery of proteins, including anti-inflammatory applications. A direct peer in the engineered exosome/secretome therapeutics space.

7Turn Biotechnologies
TypeEmerging player
Description

Turn Bio is an early-stage company developing mRNA-based epigenetic reprogramming therapies to reverse cellular aging. An emerging player in the regenerative/longevity space that overlaps with Micregen's anti-aging and degenerative disease pipeline.

TypeDirect peer
Description

Prolacta develops human milk-based nutritional and biologic products specifically for premature infants, including for NEC. Closest direct competitor in the NICU/preterm orphan indication that Micregen's MRG1061 targets.

TypeDirect peer
Description

Capricor develops exosome-based and cell-derived therapeutics (e.g., CAP-1002, exosomes from cardiosphere-derived cells) for rare diseases and regenerative indications. Closest direct competitor to Micregen's cell-free stem cell-derived secretome platform targeting orphan and degenerative conditions.

10ReAlta Life Sciences
TypeEmerging player
Description

ReAlta is a clinical-stage biotech developing anti-inflammatory peptides (RLS-0071) for NEC and other rare inflammatory diseases. Emerging player in the same NEC indication Micregen is targeting, validating the unmet need.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Micregen

Regenerative Medicine Biologicsmicregen.com

Micregen is a privately held UK biotechnology company developing cell-free, stem cell-derived therapeutics via its proprietary Secretomix® platform, with lead candidate MRG1061 advancing toward clinical trials for neonatal orphan diseases NEC and BPD.

What Micregen does

Micregen is a privately held UK biotechnology company developing cell-free, stem cell-derived therapeutics through its proprietary Secretomix® platform. Founded in 2015 by Barry Sharples and Stephen Ray, the company is headquartered at Thames Valley Science Park in Reading with a commercial office at Alderley Park, Cheshire, and operates with a lean team of 11–50 staff. Its lead therapeutic candidate, MRG1061, is being advanced toward combined Phase I/II clinical trials in the UK for two neonatal orphan indications — necrotising enterocolitis (NEC) and bronchopulmonary dysplasia (BPD) — both of which lack effective pharmacological treatments and carry peak forecasted annual sales above $1 billion each.

The Secretomix® platform produces multi-factorial biologics — including miRNA, extracellular vesicles (exosomes), cytokines, anti-inflammatory factors, lipids, and growth factors — from a proprietary GMP-certified allogeneic stem cell bank. Products are cell-free, allogeneic, scalable, storable under standard (non-ultra-cold) conditions, and administerable off-the-shelf, addressing the principal limitations of conventional stem cell therapies (graft rejection, graft-versus-host disease, tumor formation, ultra-cold logistics). The platform has produced more than 2,000 characterized components in lead formulations, with a completed suite of in-process, potency, and release assays supporting clinical-grade manufacture. Beyond the lead neonatal program, Micregen is pursuing preclinical programs in neurodegeneration (Alzheimer's, MND/ALS) and hallmarks-of-ageing applications.

Micregen is pre-revenue and funded to date by approximately £5.4 million in cumulative capital, comprising a £5 million funding round completed in April 2021 and a £395,000 Innovate UK Smart Award granted in September 2018. The company is currently raising an investment round to fund Phase I/II clinical development. It holds an MHRA Innovation Passport, ILAP membership (December 2022), UKRI Scale-Up Programme selection (January 2023), and the UK Pharma Industry Awards Innovation of the Year (2023), and is supported by collaborations with Great Ormond Street Hospital, SickKids Toronto, Washington University, and the University of Bradford. Future revenue, once approved, is expected from sale of orphan-disease therapeutics distributed via hospital pharmacies and specialty channels; pricing for investigational products is not publicly disclosed.

Micregen firmographics

Firmographics
Name
Micregen
Legal name
Micregen Ltd
Website
https://micregen.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Micregen is a privately held UK biotechnology company developing cell-free, stem cell-derived therapeutics via its proprietary Secretomix® platform, with lead candidate MRG1061 advancing toward clinical trials for neonatal orphan diseases NEC and BPD.
Ownership category
akta.pro rank

Micregen industry classification

Industry
Product category
Regenerative Medicine Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Stem cell therapeutics
  • Regenerative medicine
  • Cell-free biologics
  • Secretome therapeutics
  • Neonatal orphan drugs

Where Micregen is headquartered

Location

Headquarters

HQ city
Reading
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Micregen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Therapeutic Product Revenue: Pre-revenue biotech company developing stem cell secretome therapeutics. Future revenue expected from sale of approved therapeutic products targeting orphan diseases (NEC, BPD) and broader degenerative/age-associated conditions. The company is currently in investment round to fund clinical trials.
  2. Investment Capital: Privately held company funded by founders, angel investors, and life science professionals. Completed £5m funding round in 2021 and £395k Innovate UK Smart Award in 2018. Currently raising capital for clinical development.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Micregen product offering

Product offering

Core offering

Micregen develops proprietary cell-free, stem cell-derived secretome therapeutics using its Secretomix® platform, produced from a GMP-certified allogeneic stem cell bank. Its lead therapeutic candidate, MRG1061, is being advanced toward clinical trials for neonatal orphan diseases including necrotising enterocolitis (NEC) and bronchopulmonary dysplasia (BPD), with additional preclinical programs targeting neurodegeneration (Alzheimer's, MND/ALS) and age-associated degenerative conditions. The company is pre-revenue and currently raising capital to fund combined Phase I/II clinical trials.

Product overview

Micregen offers a unified platform technology called Secretomix®, which generates cell-free stem cell-derived therapeutic products. The platform produces multi-component biologics including miRNA, extracellular vesicles (exosomes), cytokines, anti-inflammatory factors, lipids, and proteins that act to enhance tissue repair and regeneration. The lead therapeutic candidate MRG1061, derived from this platform, is advancing toward clinical trials for neonatal conditions. The Secretomix® platform is designed to create various secretome formulations targeting conditions from rare pediatric diseases to age-associated degenerative conditions.

Differentiator

Problem solved

Functional benefit

Brands

  • Secretomix®: Proprietary platform technology for producing cell-free, stem cell-derived secretome therapeutics for regenerative medicine applications.

Products and services

  • Secretomix® Platform Proprietary cell-free, stem cell-derived secretome therapeutic platform. Secretomix® products are multi-component biologics (miRNA, extracellular vesicles/exosomes, cytokines, anti-inflammatory factors, lipids, and proteins including growth factors) produced from a GMP-certified allogeneic stem cell bank. The platform yields scalable, storable, off-the-shelf therapeutics that avoid graft rejection, graft-versus-host disease and tumour risk and can be administered immediately at the point of care.
  • MRG1061 Micregen's lead Secretomix® therapeutic candidate, a tailored combination of regenerative and anti-inflammatory factors designed to reduce intestinal injury, promote healing and improve survival outcomes in preterm infants with necrotising enterocolitis (NEC) and bronchopulmonary dysplasia (BPD) — orphan neonatal diseases with no effective pharmacological treatments today and combined peak-sales potential above $2B.

Quantifiable outcome

  • Measurable preservation of memory function in preclinical Alzheimer's models
  • +4 more outcomes

Companies that use Micregen

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Micregen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Micregen partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core, secondary and minor.

  • NEC-ACCELERATOR ConsortiumcoreStrategic or Co-development Partner · 17 July 2024Micregen featured as 'Industry Partner' in Nature's Pediatric Research paper for NEC-ACCELERATOR (NECrotizing Enterocolitis-ACceleration of CELl-based & Regenerative medicine Advancements for Translation in neOnates). The consortium aims to enhance clinical translation of stem cell-based potential treatments for NEC in neonates. This partnership validates Micregen's scientific approach and provides peer-reviewed publication support.
  • The Hospital for Sick Children (SickKids), TorontocoreStrategic or Co-development PartnerSickKids is Canada's most research-intensive hospital and No.1 paediatric hospital in the world (2022 Newsweek). Micregen collaborates on various preclinical studies. Dr. Augusto Zani serves as Staff Surgeon and has made landmark discoveries in amniotic fluid stem cells. Preclinical studies conducted in USA, UK, and Canada.
  • Great Ormond Street Hospital (GOSH) / UCL Institute of Child HealthcoreStrategic or Co-development PartnerGOSH ranked No. 3 paediatric hospital in the world (2022 Newsweek). Micregen has worked with GOSH specialists for over ten years on preclinical studies and clinical advice for trial preparation. MRC grant awarded to partnership for PhD programme on Secretomix® as therapeutic option in NEC, led by Dr. Loukogeorgakis and Dr. Sivaraj.
  • University of BradfordsecondaryStrategic or Co-development PartnerCollaborating on validation of Secretomix® as a therapeutic for neurodegeneration. Studies designed to determine efficacy of Secretomix® in various disease models for Alzheimer's and Motor Neurone Disease.
  • Washington University School of MedicinesecondaryStrategic or Co-development PartnerCollaborating with world-renowned neonatal surgeon and professor on research into Bronchopulmonary Dysplasia and other neonatal lung indications. Washington University is recognized as one of the top 10 medical schools in the United States.
  • Boyds ConsultantscoreImplementation/ SI/ Consulting PartnerRegulatory advisors specializing in pharma, biotech, and spinouts supporting new medicine development. Boyds has advised Micregen since 2018 with extensive experience in novel advanced biologic therapies and trusted relationships with regulatory bodies, enabling support in scenarios with limited or no precedents.
  • Addleshaw Goddard LLPcoreImplementation/ SI/ Consulting PartnerCorporate lawyers first established in 1775, globally recognized with clients including many UK FTSE100 listed companies. Their cross-disciplinary healthcare team has in-depth knowledge across virtually every area of healthcare.
  • Cowgill HollowaysecondaryImplementation/ SI/ Consulting PartnerOne of the North West's leading independent firms of Chartered Accountants and Business Advisors providing financial and business advisory services.
  • Handelsbanken plcminorOthersFounded in 1871, Handelsbanken is one of the world's strongest banks with home markets in Denmark, Finland, Netherlands, Norway, Sweden, and the UK, providing banking services to Micregen.
  • Karolinska InstituteminorGTM or Marketing PartnerMicregen sponsored the 37th International Symposium on Pediatric Surgical Research 2024 held at Karolinska Institute in Stockholm, Sweden. Conference united clinicians and researchers engaged in pioneering research on pediatric diseases.
  • Longevity Investors ConferenceminorGTM or Marketing PartnerMicregen Co-founder Barry Sharples was one of 10 exclusive global speakers at the invite-only 2024 Longevity Investors Conference in Gstaad, Switzerland. Event brought together leading figures in longevity including Eric Verdin (Buck Institute), Dr. Nir Barzilai, Aubrey de Grey, and Bryan Johnson.

Scale indicators10 records

Recent moves8 records

Expansion highlights5 records

Micregen competitors and assessment

Company assessment

Broad incumbents

  • Athersys: Athersys develops MultiStem, an allogeneic stem cell therapy for inflammatory, neurological, and acute conditions. A broader incumbent in regenerative cell therapy with multi-indication ambitions similar to Micregen's pipeline breadth.
  • Pluristem Therapeutics: Pluristem develops placenta-derived allogeneic cell therapies for inflammatory, ischemic, and hematological conditions. Comparable as a broader stem cell therapy incumbent targeting similar regenerative and anti-inflammatory mechanisms.
  • Mesoblast: Mesoblast is a late-stage commercial regenerative medicine company with allogeneic cell therapies (e.g., remestemcel-L) for inflammatory and rare diseases. A broader incumbent in the cell-therapy regenerative medicine space overlapping Micregen's anti-inflammatory mechanism.

Direct peers

  • Evox Therapeutics: Evox is a UK-based biotech engineering exosomes for delivery of nucleic acids and proteins to treat rare diseases. Directly comparable to Micregen in leveraging extracellular vesicles/secretomes as a therapeutic modality and in targeting rare and serious diseases.
  • Cynata Therapeutics: Cynata develops iPSC-derived mesenchymal stem cell therapies with an off-the-shelf, scalable manufacturing model. Comparable in offering allogeneic, scalable stem cell-derived therapeutics, including in inflammatory and rare disease indications.
  • ILIAS Biologics: ILIAS Biologics develops engineered exosomes (EXO-LOAD technology) for therapeutic delivery of proteins, including anti-inflammatory applications. A direct peer in the engineered exosome/secretome therapeutics space.
  • Prolacta Bioscience: Prolacta develops human milk-based nutritional and biologic products specifically for premature infants, including for NEC. Closest direct competitor in the NICU/preterm orphan indication that Micregen's MRG1061 targets.
  • Capricor Therapeutics: Capricor develops exosome-based and cell-derived therapeutics (e.g., CAP-1002, exosomes from cardiosphere-derived cells) for rare diseases and regenerative indications. Closest direct competitor to Micregen's cell-free stem cell-derived secretome platform targeting orphan and degenerative conditions.

Emerging players

  • Turn Biotechnologies: Turn Bio is an early-stage company developing mRNA-based epigenetic reprogramming therapies to reverse cellular aging. An emerging player in the regenerative/longevity space that overlaps with Micregen's anti-aging and degenerative disease pipeline.
  • ReAlta Life Sciences: ReAlta is a clinical-stage biotech developing anti-inflammatory peptides (RLS-0071) for NEC and other rare inflammatory diseases. Emerging player in the same NEC indication Micregen is targeting, validating the unmet need.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Micregen social profiles

Digital presence

Micregen compliance and trust

Trust signal

Compliance2 records

Micregen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Micregen leadership team

Management profile

Number of profiles

Profiles10 records

Micregen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Micregen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Micregen

What does Micregen do?

Micregen develops proprietary cell-free, stem cell-derived secretome therapeutics using its Secretomix® platform, produced from a GMP-certified allogeneic stem cell bank. Its lead therapeutic candidate, MRG1061, is being advanced toward clinical trials for neonatal orphan diseases including necrotising enterocolitis (NEC) and bronchopulmonary dysplasia (BPD), with additional preclinical programs targeting neurodegeneration (Alzheimer's, MND/ALS) and age-associated degenerative conditions. The company is pre-revenue and currently raising capital to fund combined Phase I/II clinical trials.

Is Micregen a public or private company?

Micregen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Micregen founded?

Micregen was founded in 2015. It employs 1 to 10 people.

Where is Micregen based?

Micregen is headquartered in Reading, United Kingdom, in the Europe region.

How does Micregen make money?

Two revenue lines are on record. Therapeutic Product Revenue is the primary driver. The others are investment Capital.

Who are Micregen's main competitors?

Broad incumbents on record are Athersys, Pluristem Therapeutics and Mesoblast. Direct peers are Evox Therapeutics, Cynata Therapeutics, ILIAS Biologics, Prolacta Bioscience and Capricor Therapeutics. Emerging players are Turn Biotechnologies and ReAlta Life Sciences.

Does Micregen have an API?

No public API is recorded for Micregen.

What industry is Micregen in?

Micregen's product category is Regenerative Medicine Biologics. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales